Showing 2781-2790 of 5621 results for "".
- New Study Shows an Eye Scan Can Detect Signs of Alzheimer’s Diseasehttps://modernod.com/news/new-study-shows-an-eye-scan-can-detect-signs-of-alzheimers-disease/2476384/Researchers from the Duke Eye Center have shown that a new, noninvasive imaging device can see signs of Alzheimer’s disease in a matter of seconds. The researchers found that the small blood vessels in the retina at the back of the eye are altered in patients with Alzheimer’s, and showed that the
- Study Demonstrates Long-Term IOP Reduction with the OMNI Surgical System Predicate Device (TRAB 360) in MIGShttps://modernod.com/news/clinical-study-demonstrates-long-term-iop-reduction-with-the-omni-surgical-system-predicate-device-trab-360-in-migs/2476378/A new, single-center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI Surgical System’s Predicate Devices (TRAB 360)
- EyePoint Pharmaceuticals Announces US Commercial Launch of Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercial-launch-of-dexycu/2476370/EyePoint Pharmaceuticals announced that it has commercially launched Dexycu (dexamethasone intraocular suspension) 9% in the United States. Dexycu is the first and only FDA approved intraocular steroid for the treatment of postoperative inflammation and is administered as a single dose at the end
- Telemedicine Eye Screenings Help Detect Glaucomahttps://modernod.com/news/telemedicine-eye-screenings-help-detect-glaucoma/2476356/A low-cost program using technicians to conduct telemedicine eye screenings can help detect glaucoma in underserved populations, according to new research, as reported by Reuters. The study targeted high-risk individuals in poorer a
- Myco Industries Debuts AB Max Advanced for Treatment of Anterior Blepharitishttps://modernod.com/news/myco-industries-debuts-ab-max-advanced-for-treatment-of-anterior-blepharitis/2476354/Myco Industries released AB MAX, a new treatment for anterior blepharitis. The AB MAX is an adapter that allows eye care professionals to increase the functionality of their Algerbrush by converting it into a multi-purpose device for treatment of the same conditions as a standard Algerbrush, as w
- FDA Grants Breakthrough Device Designation to Concussion Assessment Devicehttps://modernod.com/news/fda-grants-breakthrough-device-designation-to-concussion-assessment-device/2476351/SyncThink announced that the FDA has granted Breakthrough Device Designation to EYE-SYNC, an objective eye-tracking platform. The EYE-SYNC platform is used to assist clinicians in evaluating visual impairments, monitor recovery, and support the rehabilitation of ocular-motor and ocular-vestibular
- Survey: Physicians Generate an Average of $2.4 Million a Year Per Hospitalhttps://modernod.com/news/survey-physicians-generate-an-average-of-2-4-million-a-year-per-hospital/2479591/While physicians are key providers of medical care at the nation’s hospitals, a new survey confirms they also are major drivers of hospital revenue. According to the survey, physicians generate an average $2,378,727 per year in net revenue on behalf of their af
- Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-raises-93-million-to-support-the-clinical-development-of-novel-treatment-for-dry-eye-disease/2476261/Oyster Point Pharma announced a $93 million Series B financing to support the development of its product portfolio for dry eye disease, explore new treatment areas, and add key talent. The company’s lead product candidates, OC-01 and OC-02, are delivered via an ocular surface-sparing nasal
- Ziemer USA Names Brad Hurt Vice President of Business Developmenthttps://modernod.com/news/ziemer-usa-names-brad-hurt-vice-president-of-business-development/2476263/Ziemer USA announced the appointment of Brad Hurt to its executive US leadership team as Vice President of Business Development. Mr. Hurt joins Ziemer USA from Bausch + Lomb Surgical, where he was most recently Vice President of US Surgical Sales. “I couldn’t be more excited to join the Zi
- WSJ: Roche Nears Deal to Buy Spark Therapeutics for Close to $5 Billionhttps://modernod.com/news/wsj-roche-nears-deal-to-buy-spark-therapeutics-for-close-to-5-billion/2476269/Swiss pharmaceutical company Roche is nearing a deal to buy Philadelphia-based biotechnology company Spark Therapeutics, according to a report in the Wall Street Journal